Article
New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Leukemia & lymphoma - 1 Jul 2009
Mascarenhas Cintia C, Cunha Anderson F, Miranda Eliana C, Zulli Roberto, Silveira Rosana A, Costa Fernando F, Pagnano Katia B B, De Souza Carmino A
Abstract excerpt
Point mutations within the ABL kinase domain are the most frequent mechanism for reactivation of kinase activity of the BCR-ABL gene and have been associated with clinical resistance to tyrosine kinase (TK) inhibitors in patients with CML, conferring a poor prognosis. T315I (Treonine-->Isoleucine) is a mutation in the exon 6 of BCR-ABL gene that makes the protein resistant to kinase inhibitors currently used for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.